Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement

Ronald S. Go, Jacob D. Gundrum

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The Ann Arbor staging was originally developed in 1971 for Hodgkin lymphoma at a time when radiation was the primary treatment [1]. It was subsequently adopted for use in non-Hodgkin lymphoma (NHL). Although the Ann Arbor staging continues to be valuable in nodal NHL, its application in extranodal NHL has limitations [2,3]. Proper staging and accurate prognosis of diffused large B-cell lymphoma (DLBCL) with isolated bilateral testicular involvement are unclear. Here we show that even lymphoma experts do not have a consensus on these issues with 60.7% choosing Stage IV and the remaining favoring either Stage IE or IIE. To determine the prognosis of DLBCL patients with isolated bilateral testicular involvement, we performed disease-specific survival analyses using data from the Surveillance Epidemiology and End Results Program (SEER). The survival was not significantly different from age-matched Stage II unilateral disease (P = 0.549) and was better when compared with Stage IV unilateral disease (P = 0.034). Our study suggests that a limited stage designation is more appropriate due to a relatively better prognosis. To provide uniform staging for clinical trial and prognostic purposes, development of site- and histology-specific modified staging for primary extranodal lymphoma involving paired organs may be warranted.

Original languageEnglish (US)
Pages (from-to)762-763
Number of pages2
JournalAmerican Journal of Hematology
Volume84
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Uncertainty
B-Cell Lymphoma
Lymphoma
SEER Program
Survival Analysis
Hodgkin Disease
Histology
Clinical Trials
Radiation
Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement. / Go, Ronald S.; Gundrum, Jacob D.

In: American Journal of Hematology, Vol. 84, No. 11, 11.2009, p. 762-763.

Research output: Contribution to journalArticle

@article{831b9239eb2c4605be72617b12a167da,
title = "Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement",
abstract = "The Ann Arbor staging was originally developed in 1971 for Hodgkin lymphoma at a time when radiation was the primary treatment [1]. It was subsequently adopted for use in non-Hodgkin lymphoma (NHL). Although the Ann Arbor staging continues to be valuable in nodal NHL, its application in extranodal NHL has limitations [2,3]. Proper staging and accurate prognosis of diffused large B-cell lymphoma (DLBCL) with isolated bilateral testicular involvement are unclear. Here we show that even lymphoma experts do not have a consensus on these issues with 60.7{\%} choosing Stage IV and the remaining favoring either Stage IE or IIE. To determine the prognosis of DLBCL patients with isolated bilateral testicular involvement, we performed disease-specific survival analyses using data from the Surveillance Epidemiology and End Results Program (SEER). The survival was not significantly different from age-matched Stage II unilateral disease (P = 0.549) and was better when compared with Stage IV unilateral disease (P = 0.034). Our study suggests that a limited stage designation is more appropriate due to a relatively better prognosis. To provide uniform staging for clinical trial and prognostic purposes, development of site- and histology-specific modified staging for primary extranodal lymphoma involving paired organs may be warranted.",
author = "Go, {Ronald S.} and Gundrum, {Jacob D.}",
year = "2009",
month = "11",
doi = "10.1002/ajh.21522",
language = "English (US)",
volume = "84",
pages = "762--763",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement

AU - Go, Ronald S.

AU - Gundrum, Jacob D.

PY - 2009/11

Y1 - 2009/11

N2 - The Ann Arbor staging was originally developed in 1971 for Hodgkin lymphoma at a time when radiation was the primary treatment [1]. It was subsequently adopted for use in non-Hodgkin lymphoma (NHL). Although the Ann Arbor staging continues to be valuable in nodal NHL, its application in extranodal NHL has limitations [2,3]. Proper staging and accurate prognosis of diffused large B-cell lymphoma (DLBCL) with isolated bilateral testicular involvement are unclear. Here we show that even lymphoma experts do not have a consensus on these issues with 60.7% choosing Stage IV and the remaining favoring either Stage IE or IIE. To determine the prognosis of DLBCL patients with isolated bilateral testicular involvement, we performed disease-specific survival analyses using data from the Surveillance Epidemiology and End Results Program (SEER). The survival was not significantly different from age-matched Stage II unilateral disease (P = 0.549) and was better when compared with Stage IV unilateral disease (P = 0.034). Our study suggests that a limited stage designation is more appropriate due to a relatively better prognosis. To provide uniform staging for clinical trial and prognostic purposes, development of site- and histology-specific modified staging for primary extranodal lymphoma involving paired organs may be warranted.

AB - The Ann Arbor staging was originally developed in 1971 for Hodgkin lymphoma at a time when radiation was the primary treatment [1]. It was subsequently adopted for use in non-Hodgkin lymphoma (NHL). Although the Ann Arbor staging continues to be valuable in nodal NHL, its application in extranodal NHL has limitations [2,3]. Proper staging and accurate prognosis of diffused large B-cell lymphoma (DLBCL) with isolated bilateral testicular involvement are unclear. Here we show that even lymphoma experts do not have a consensus on these issues with 60.7% choosing Stage IV and the remaining favoring either Stage IE or IIE. To determine the prognosis of DLBCL patients with isolated bilateral testicular involvement, we performed disease-specific survival analyses using data from the Surveillance Epidemiology and End Results Program (SEER). The survival was not significantly different from age-matched Stage II unilateral disease (P = 0.549) and was better when compared with Stage IV unilateral disease (P = 0.034). Our study suggests that a limited stage designation is more appropriate due to a relatively better prognosis. To provide uniform staging for clinical trial and prognostic purposes, development of site- and histology-specific modified staging for primary extranodal lymphoma involving paired organs may be warranted.

UR - http://www.scopus.com/inward/record.url?scp=70449595655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449595655&partnerID=8YFLogxK

U2 - 10.1002/ajh.21522

DO - 10.1002/ajh.21522

M3 - Article

C2 - 19856427

AN - SCOPUS:70449595655

VL - 84

SP - 762

EP - 763

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -